triple agonist glp 1 Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing 💉 A triple-action once-weekly injection

Description

Why Choose Troy Watson for Your First Week of Semaglutide GLP-1 Treatment at Set Point Medical Weight Loss Clinic Is weight loss noticeable during the first week of Semaglutide GLP-1 treatment

In comparison to placebo, liraglutide treatment reduced the prevalence of NAFLD by two-thirds, the amount of fat in the liver by 44%, visceral adipose tissue by 18%, and body weight by 5.2 kg (5.6%) (199)

doi: 10.1093/eurheartj/ehad192

Expanded FDA Indications In 2024/2025 The potential uses for GLP-1s are expanding rapidly, moving well beyond their original purpose of diabetes management